Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol

University of California, Department of Veterans Affairs Medical Center, San Francisco, CA 94121, USA.
Journal of NeuroVirology (Impact Factor: 3.32). 06/2009; 15(4):324-33. DOI: 10.1080/13550280902973960
Source: PubMed

ABSTRACT Treatment with antiretroviral therapy (ART) has greatly reduced the incidence of dementia. The goal of this longitudinal study was to determine if there are ongoing macrostructural brain changes in human immunodeficiency virus-positive (HIV + ) individuals treated with ART. To quantify brain structure, three-dimensional T1-weighted magnetic resonance imaging (MRI) scans were performed at baseline and again after 24 months in 39 HIV+ patients on ART and 30 HIV- controls. Longitudinal changes in brain volume were measured using tissue segmentation within regions of interest and deformation morphometry. Measured by tissue segmentation, HIV+ patients on ART had significantly (all P<.05) greater rates of white matter volume loss than HIV- control individuals. Compared with controls, the subgroup of HIV+ individuals on ART with viral suppression also had significantly greater rates of white matter volume loss. Deformation morphometry confirmed these results with more specific spatial localization. Deformation morphometry also detected greater rates of gray matter and white matter loss in the subgroup of HIV+ individuals with detectable viral loads. These results provide evidence of ongoing brain volume loss in HIV+ individuals on stable ART, possibly suggesting ongoing cerebral injury. The presence of continuing injury raises the possibility that HIV+ individuals-even in the presence of viral suppression in the periphery-are at greater risk for future cognitive impairments and dementia and possibly faster cognitive decline. Therefore, HIV+ individuals on ART should be monitored for cognitive decline, and treatments that reduce ongoing neurological injury should be considered.

Download full-text


Available from: Dieter Johannes Meyerhoff, Mar 25, 2014
  • Source
    • "Methamphetamine use may also cause hypertrophy of the white matter (perhaps due to inflammation); although the cause and consistency of the white matter effects of meth are not well-understood, some cohorts deliberately assess HIV participants with co-morbid IV drug use, where the balance of effects tends to reflect a combination of viral effects and those of chronic drug use. Recent evidence for white matter changes in HIV+ participants includes faster rates of white matter volume loss in HIV+ patients on stable cART with viral suppression (Cardenas et al., 2009), lower white matter fractional anisotropy as well as greater brain network deficits measured by diffusion tensor imaging (Chen et al., 2009; Jahanshad et al., 2012; Nir et al., 2013; Pfefferbaum et al., 2007; Pfefferbaum et al., 2009; Ragin et al., 2004; Tate et al., 2010; Wu et al., 2006). In the HIVNC cohort and a separate cohort named CNS HIV Antiretroviral Therapy Effects Research (CHARTER), nadir CD4 + count has been associated with lower total white matter and subcortical gray matter volumes (Cohen et al., 2010b; Jernigan et al., 2011), as well as lower corpus callosum volumes (Tate et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive impairment and brain injury are common in people with HIV/AIDS, even when viral replication is effectively suppressed with combined antiretroviral therapies (cART). Metabolic and structural abnormalities may promote cognitive decline, but we know little about how these measures relate in people on stable cART. Here we used tensor-based morphometry (TBM) to reveal the 3D profile of regional brain volume variations in 210 HIV + patients scanned with whole-brain MRI at 1.5 T (mean age: 48.6 ± 8.4 years; all receiving cART). We identified brain regions where the degree of atrophy was related to HIV clinical measures and cerebral metabolite levels assessed with magnetic resonance spectroscopy (MRS). Regional brain volume reduction was linked to lower nadir CD4 + count, with a 1–2% white matter volume reduction for each 25-point reduction in nadir CD4 +. Even so, brain volume measured by TBM showed no detectable association with current CD4 + count, AIDS Dementia Complex (ADC) stage, HIV RNA load in plasma or cerebrospinal fluid (CSF), duration of HIV infection, antiretroviral CNS penetration-effectiveness (CPE) scores, or years on cART, after controlling for demographic factors, and for multiple comparisons. Elevated glutamate and glutamine (Glx) and lower N-acetylaspartate (NAA) in the frontal white matter, basal ganglia, and mid frontal cortex — were associated with lower white matter, putamen and thalamus volumes, and ventricular and CSF space expansion. Reductions in brain volumes in the setting of chronic and stable disease are strongly linked to a history of immunosuppression, suggesting that delays in initiating cART may result in imminent and irreversible brain damage.
    Clinical neuroimaging 12/2013; 3:132–142. DOI:10.1016/j.nicl.2013.07.009 · 2.53 Impact Factor
  • Source
    • "A longitudinal study performed during the pre-HAART era found greater loss of WM and caudate, with greater enlarged cerebrospinal fluid (CSF) space in HIV subjects than SN controls over a 2-year follow-up period, especially in HIV subjects who were medically symptomatic or had lower CD4 counts (Stout et al. 1998). A more recent study of HIV subjects maintained on more potent antiretroviral (ARV) regimens still found that, over a 24-month period, WM loss was greater in HIV subjects than SN controls (Cardenas et al. 2009). Recent morphometry studies, using an automated image segmentation technique, found that both HIV and aging independently contributed to volume reductions in many brain regions (Ances et al. 2012b; Chang et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Highly active antiretroviral therapy (HAART) has increased life expectancy among HIV-infected individuals, and by 2015, at least half of all HIV-infected individuals will be over 50 years of age. Neurodegenerative processes associated with aging may be facilitated by HIV-1 infection, resulting in premature brain aging. This review will highlight brain abnormalities in HIV patients in the setting of aging, focusing on recent neuroimaging studies of the structural, physiological, functional and neurochemical changes. Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy studies performed during the pre-HAART era or on antiretroviral-naive subjects suggest an accelerated aging process, while those on HAART-treated subjects suggest premature brain atrophy. Diffusion tensor imaging studies yielded conflicting findings on the relationship between HIV and age in neuroasymptomatic individuals. Functional MRI studies found evidence of premature or accelerated aging processes in the brains of HIV subjects. Lastly, many age-related illnesses such as diabetes, stroke, and depression, as well as comorbid substance abuse, may further exacerbate the aging process in the HIV-infected brain, leading to premature or accelerated age-related brain changes. Given the different pathologic or physiologic changes in the brain assessed by the different neuroimaging techniques, using a multimodal approach in longitudinal follow-up studies is recommended for future studies.
    Journal of NeuroVirology 06/2012; 18(4):291-302. DOI:10.1007/s13365-012-0114-1 · 3.32 Impact Factor
  • Source
    • "However, milder forms of cognitive impairment frequently occur, despite effective viral control (Simioni et al., 2009). In subjects on stable CART, there is evidence of ongoing brain volume loss, white matter injury, hippocampal involvement, metabolic disturbances, synaptic pruning and dendritic damage that is not associated with treatment failure, viral load or CD4 counts (McArthur et al.; Gelman, 2007; Chang et al., 2008; McMurtray et al., 2008; Pelle et al., 2008; Cardenas et al., 2009; Gongvatana et al., 2009; Khanlou et al., 2009; Cohen et al., 2010). Together, these observations suggest that CART is not sufficient to prevent neurocognitive damage, and that the loss of nerve terminals may be central to the pathogenesis of CART. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Infection by the human immunodeficiency virus (HIV) can result in debilitating neurological syndromes collectively known as HIV-associated neurocognitive disorders. Although the HIV coat protein gp120 has been identified as a potent neurotoxin that enhances NMDA receptor function, the exact mechanisms for this effect are not known. Here we provide evidence that gp120 activates two separate signaling pathways that converge to enhance NMDA-evoked calcium flux by clustering NMDA receptors in modified membrane microdomains. gp120 enlarged and stabilized the structure of lipid microdomains on dendrites by mechanisms that involved a redox-regulated translocation of a sphingomyelin hydrolase (neutral sphingomyelinase-2) to the plasma membrane. A concurrent pathway was activated that accelerated the forward traffic of NMDA receptors by a PKA-dependent phosphorylation of the NR1 C-terminal serine 897 (masks an ER retention signal), followed by a PKC-dependent phosphorylation of serine 896 (important for surface expression). NMDA receptors were preferentially targeted to synapses and clustered in modified membrane microdomains. In these conditions, NMDA receptors were unable to laterally disperse and did not internalize, even in response to strong agonist induction. Focal NMDA-evoked calcium bursts were enhanced by threefold in these regions. Inhibiting membrane modification or NR1 phosphorylation prevented gp120 from accelerating the surface localization of NMDA receptors. Disrupting the structure of membrane microdomains after gp120 treatments restored the ability of NMDA receptors to disperse and internalize. These findings demonstrate that gp120 contributes to synaptic dysfunction in the setting of HIV infection by interfering with NMDA receptor trafficking.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 11/2011; 31(47):17074-90. DOI:10.1523/JNEUROSCI.4072-11.2011 · 6.75 Impact Factor
Show more